Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

scientific article

Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/SJ.BJC.6604769
P932PMC publication ID2600696
P698PubMed publication ID18985033
P5875ResearchGate publication ID23452291

P50authorAthanasios DimopoulosQ26338766
H P KalofonosQ56432806
George FountzilasQ56432880
Urania DafniQ56605609
P2093author name stringD Pectasides
G Aravantinos
H Gogas
H Linardou
E Razis
E Briasoulis
C Christodoulou
P Papakostas
G Zografos
T Economopoulos
A K Koutras
K T Kalogeras
R M Wirtz
Hellenic Cooperative Oncology Group (HeCOG)
E Timotheadou
P2860cites workA naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4Q24291286
The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cellsQ24293729
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimeraQ24595150
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneQ27860693
The deaf and the dumb: the biology of ErbB-2 and ErbB-3Q28185247
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsQ29547513
The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients*Q33188817
HER2/neu in systemic therapy for women with breast cancer: a systematic reviewQ33291068
Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.Q33968565
Reporting recommendations for tumor marker prognostic studiesQ81236405
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patientsQ81414756
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerQ34601123
HER-2 and topoisomerase II as predictors of response to chemotherapyQ34747499
The clinical evaluation of HER-2 status: which test to use?Q35084775
Recommendations for HER2 testing in the UK.Q35395505
Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysisQ35789663
Oncogenic growth factor receptors: implications for signal transduction therapyQ35818569
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.Q36135449
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patientsQ36643014
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancerQ38446760
Comparative multi-methodological measurement of ERBB2 status in breast cancerQ40584056
Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.Q41093419
Prognostic value of ERBB family mRNA expression in breast carcinomasQ43461671
Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-upQ43695203
c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survivalQ43926200
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.Q44362100
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancerQ44503047
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinomaQ44969545
Adjuvant docetaxel for node-positive breast cancerQ46522790
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patientsQ46580491
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupQ46691182
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.Q46813500
Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breastQ46892411
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyQ46991232
Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?Q47793792
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Q53394493
EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.Q53810400
Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.Q54628922
HER2 and Response to Paclitaxel in Node-Positive Breast CancerQ57578418
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancerQ59616875
c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancerQ64019053
Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanismsQ71536089
Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assayQ73269384
Active signaling by Neu in transgenic miceQ77430527
Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancerQ77673978
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcomeQ79918229
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP systemQ80358653
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trialsQ80408348
P433issue11
P407language of work or nameEnglishQ1860
P304page(s)1775-1785
P577publication date2008-11-04
P1433published inBritish Journal of CancerQ326309
P1476titleEvaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study
P478volume99

Reverse relations

cites work (P2860)
Q36223407Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy
Q92111598Application of Multiplex Ligation-Dependent Probe Amplification in Determining the Copy Number Alterations of HER Gene Family Members in Invasive Ductal Breast Carcinoma
Q54286036Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
Q27852062Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
Q54395374Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Q33921374ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer
Q89767940ErbB4 3'-UTR Variant (c.*3622A>G) is Associated with ER/PR Negativity and Advanced Breast Cancer
Q35663809Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study
Q60046313Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study
Q54297439Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas.
Q54642874Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study.
Q33644491Genetically dependent ERBB3 expression modulates antigen presenting cell function and type 1 diabetes risk
Q35744973HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
Q39368710HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy
Q31134061Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue
Q60920835Low HIF-1α and low EGFR mRNA Expression Significantly Associate with Poor Survival in Soft Tissue Sarcoma Patients; the Proteins React Differently
Q33570512MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer
Q27853060Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
Q37658764Potential of ErbB4 antibodies for cancer therapy.
Q43244620Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index
Q42148898Prognostic significance of HER3 in patients with malignant solid tumors
Q90291834Quantification of EGFR family in canine mammary ductal carcinomas in situ: implications on the histological graduation
Q34518357STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.
Q36598709Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research
Q26864668Targeting of erbB3 receptor to overcome resistance in cancer treatment
Q35357793The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines
Q24309041WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer

Search more.